OSE-2101

OSE Immunotherapeutics reported total income of €83.4 million for 2024, with a cash position of €64.2 million ensuring financial visibility until Q1 2027.

A novel approach combining total marrow and lymphoid irradiation (TMLI) at 20 Gy with post-transplant cyclophosphamide demonstrated remarkable outcomes in AML patients undergoing transplantation, with 84% overall survival at 2 years.

The TEDOPaM Phase 2 trial met its primary endpoint, demonstrating that OSE2101 (Tedopi) combined with FOLFIRI chemotherapy achieved a statistically significant improvement in one-year overall survival rate for advanced pancreatic cancer patients.

Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.